Cardiovascular Medicine

1 pages, 76 KB

Open AccessCommunication

Jahresbericht 2008 der Arbeitsgruppe «Erwachsene mit Angeborenem Herzfehler» (WATCH) der SGK

by Kurt Mayer, Pedro Trigo-Trindade, Maurice Beghetti, Nicole Sekarski, René Prêtre and Markus Schwerzmann

Cardiovasc. Med. 2009, 12(9), 254; https://doi.org/10.4414/cvm.2009.01441 - 18 Sep 2009

Viewed by 56

Abstract

An der SGK 2008 in Bern wurden keine neuen ordentlichen oder ausserordentlichen Mitglieder aufgenommen [...] Full article

1 pages, 79 KB

Open AccessCommunication

Jahresbericht 2008 der Arbeitsgruppe «Kardiovaskuläre Biologie» der Schweizerischen Gesellschaft für Kardiologie

by Zusammensetzung M. Matter, Marijke Brink, Brink R. Kwak Chanson, Zhihong Yang, Thierry Pedrazzini, Christian Zuppinger and Thomas M. Suter

Cardiovasc. Med. 2009, 12(9), 253; https://doi.org/10.4414/cvm.2009.01443 - 18 Sep 2009

Viewed by 66

Abstract

Tätigkeit der Arbeitsgruppe
Das wissenschaftliche Meeting 2008 hat als «14. Cardiovascular Biology and Clinical Implications Meeting» am 2. und 3 [...] Full article

2 pages, 1379 KB

Open AccessInteresting Images

My Heart Dances

by Marcus Mutschelknauss, Hans Rickli and Peter Ammann

Cardiovasc. Med. 2009, 12(9), 251; https://doi.org/10.4414/cvm.2009.01442 - 18 Sep 2009

Cited by 1 | Viewed by 60

Abstract

Case presentation
A 33-year old woman was admitted for persistent palpitations over the past six years [...] Full article

► Show Figures

Figure 1

6 pages, 315 KB

Open AccessEditorial

Management der Pulmonalen Hypertonie – Was Ist neu Seit Dana Point?

by Silvia Ulrich Somaini

Cardiovasc. Med. 2009, 12(9), 245; https://doi.org/10.4414/cvm.2009.01440 - 18 Sep 2009

Viewed by 64

Abstract

Management of pulmonary hypertension – news from Dana Point
Recently, the 4th WHO conference on pulmonary hypertension (PH) was hold in Dana Point. Thereby, new treatment algorhythms were developed. Specific PH therapy with prostanoids, endothelin-receptor antagonists and phosphodiesterase-5-inhibitors is now also recommended for [...] Read more.

Management of pulmonary hypertension – news from Dana Point
Recently, the 4th WHO conference on pulmonary hypertension (PH) was hold in Dana Point. Thereby, new treatment algorhythms were developed. Specific PH therapy with prostanoids, endothelin-receptor antagonists and phosphodiesterase-5-inhibitors is now also recommended for patients with pulmonary arterial hypertension (PAH) in NYHA/WHO class II. Combination therapy is recommended for PAH patients not sufficiently responding to monotherapy, however, the best combination has still to be investigated in clinical trials. If PAH patients are stable on therapy, closely supervised training can be recommended. For chronic thromboembolic PH (CTEPH), pulmonary endarterectomy remains the treatment of choice. CTEPH patients not eligible for surgery may profit from drug therapy in analogy to PAH patients. Patients with PH due to chronic heart or lung diseases should be treated as efficiently as possible for their underlying condition. Many new compounds for the treatment of PH are currently under investigation, including sGC stimulators, thyrosin kinase inhibitors and serotonin antagonists Full article

► Show Figures

Figure 1

6 pages, 264 KB

Open AccessProceeding Paper

Lipid-Lowering Therapies and Liver Enzymes

by Delphine Stoll, Roger Darioli and Nicolas Rodondi

Cardiovasc. Med. 2009, 12(9), 239; https://doi.org/10.4414/cvm.2009.01446 - 18 Sep 2009

Viewed by 217

Abstract

Lipid-lowering drugs, especially HMGCoA reductase inhibitors, are widely used in the treatment and prevention of cardiovascular disease. They are generally well tolerated. The main, but uncommon, adverse effects of statins are myopathy and an increase in hepatic transaminases. This review focuses on concerns [...] Read more.

Lipid-lowering drugs, especially HMGCoA reductase inhibitors, are widely used in the treatment and prevention of cardiovascular disease. They are generally well tolerated. The main, but uncommon, adverse effects of statins are myopathy and an increase in hepatic transaminases. This review focuses on concerns surrounding the safety of lipid-lowering therapy as it affects liver function. Asymptomatic statin-associated elevations in aminotransferases are common and doserelated, but they are not indicative of liver damage. Liver injury attributable to lipid-lowering therapies is very uncommon. Routine monitoring of liver function is not supported by the available evidence but is still recommended by the FDA. Decompensated cirrhosis, acute liver failure and significant cholestasis are contraindications for statin therapy, but not compensated chronic liver disease such as non-alcoholic fatty liver disease. Possible interactions (mainly with CYP3A4 inhibitors) deserve particular attention, and when statin therapy is needed the lowest effective dose should be prescribed in adults at risk for liver problems. Full article

► Show Figures

Figure 1

5 pages, 462 KB

Open AccessProceeding Paper

The Right Ventricle in Tetralogy of Fallot

by Emanuela Valsangiacomo Büchel and Dominik Stambach

Cardiovasc. Med. 2009, 12(9), 234; https://doi.org/10.4414/cvm.2009.01445 - 18 Sep 2009

Cited by 2 | Viewed by 93

Abstract

Surgical repair of tetralogy of Fallot (TOF) may be followed by various conditions and residual findings, early postoperatively or late during follow-up. Most of these conditions affect the right ventricular outflow tract and the pulmonary arteries and thus, indirectly, the right ventricle.
This [...] Read more.

Surgical repair of tetralogy of Fallot (TOF) may be followed by various conditions and residual findings, early postoperatively or late during follow-up. Most of these conditions affect the right ventricular outflow tract and the pulmonary arteries and thus, indirectly, the right ventricle.
This paper discusses the role of the right ventricle during the natural history of repaired TOF. The different imaging methods used to assess the function of the right ventricle in relation to this congenital heart disease are highlighted. Particular attention is focused on the volume overloaded right ventricle, as this condition is nowadays a subject of intense discussion, particularly regarding the appropriate timing for pulmonary valve replacement. The most recent literature on this topic is briefly reviewed. In summary, preservation of right ventricular function and prevention of right ventricular arrhythmias are crucial for these patients’ survival and outcome. Full article

► Show Figures

Figure 1

5 pages, 166 KB

Open AccessViewpoint

«Lies, Damn Lies, and Statistics»: Bemerkungen zu den Outcome-Zahlen des Bundesamtes für Gesundheit

by Thomas F. Lüscher

Cardiovasc. Med. 2009, 12(9), 229; https://doi.org/10.4414/cvm.2009.01444 - 18 Sep 2009

Viewed by 60

Abstract

«Lies, damn lies, and statistics»…
Benjamin Disraeli, britischer Premierminister von 1874–1880 (Abb. 1), soll diese Worte gesprochen haben, die später von Mark Twain popularisiert wurden: «There are three kinds of lies: Lies, damn lies, and statistics» [...] Full article

► Show Figures

Figure 1

Journal Menu

Journal Browser

Cardiovasc. Med., Volume 12, Issue 9 (09 2009) – 7 articles

Further Information

Guidelines

MDPI Initiatives

Follow MDPI